Apellis Director Mikael Dolsten Exits All Shares and Options in Biogen’s $41‑Per‑Share Tender Offer

TL;DR Mikael Dolsten, a director of Apellis Pharmaceuticals, sold all his Apellis shares and options in Biogen’s $41‑per‑share tender offer, receiving cash plus contingent value rights. After the transaction he holds no direct stake in the company.

Context Biogen launched a tender offer to acquire Apellis, offering $41 in cash for each share plus one contingent value right (CVR). The CVR may pay up to an additional $4 per share if certain milestones are met. The offer closed and the companies merged, with Apellis becoming a wholly owned subsidiary of Biogen.

Key Facts - Dolsten disposed of 14,312 Apellis common shares. - He also disposed of 24,135 stock options tied to Apellis. - Each share exchanged for $41 cash and one CVR. - The CVR could deliver up to $4 extra per share upon milestone achievement. - After the dispositions, Dolsten reported zero direct Apellis shares or options.

What It Means The sales reflect the mechanics of the merger rather than a personal view on Apellis’s prospects. Dolsten received immediate cash and a potential future payout contingent on Biogen’s post‑merger performance. Because the transactions were required by the deal structure, they carry little signaling value about his confidence in the company.

What to watch next Investors will monitor whether the CVR milestones are triggered, which could add up to $4 per share in additional cash. Additionally, the integration of Apellis’s pipeline into Biogen’s portfolio will be closely watched for any impact on future revenue streams.